Blog of the Day
posted by wliauw, Feb 08, 2010It is a mistake to assume that just because proposed reforms would benefit the pharmaceutical industry that it is neccessarily bad for health consumers. Properly regulated reforms to clinical trials standards will also benefit Australian patients.
Clinical trials involving volunteer patients form an integral part of the development of new healthcare interventions.
Clinical trials also form an important industry in Australia; injecting an estimated $450 million dollars to the Australian knowledge economy.
But like the healthcare system itself the clinical trials industry is ailing. Many barriers to the more efficient approval and conduct of clinical trials are reducing the incentives for both local and foreign companies to conduct clinical trials in Australia.
The governance of clinical trials in Australia is currently the matter of a major debate being coordinated by a subcommittee of the Pharmaceutical Industry Working Group,
the Clinical Trials Action Group, co-chaired by the Hon. Richard Marles MP, Parliamentary Secretary for Innovation and Industry, and the Hon. Mark Butler MP, Parliamentary Secretary for Health. The Action Group has
called for submissions related to improving the operating environment of clinical trials in Australia.
read more »